NCT05909423View on ClinicalTrials.gov

Combining Intratumoral Flu Vaccine and Systemic Pembrolizumab in Patients With Early pMMR Colorectal Cancer

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 1, 2023

Primary Completion Date

September 1, 2025

Study Completion Date

September 1, 2028

Conditions

Colorectal Cancer

Interventions

DRUG

Influenza vaccine

Intratumoral influenza vaccine treatment, administered via endoscopic procedure

DRUG

Pembrolizumab

Single dose pembrolizumab treatment

Trial Locations (1)

4600

Center for Surgical Science, Department of Surgery, Zealand University Hospital, Koege

All Listed Sponsors

collaborator

Slagelse Hospital

OTHER

lead

Zealand University Hospital

OTHER

NCT05909423 - Combining Intratumoral Flu Vaccine and Systemic Pembrolizumab in Patients With Early pMMR Colorectal Cancer | Biotech Hunter | Biotech Hunter